Merck Animal Health Announces Availability of SEQUIVITY® IAV-S NA for Swine Influenza

The novel vaccine is the first to use only the influenza neuraminidase (NA) surface  antigen to vaccinate pigs against influenza strains H1N1, H1N2 and H3N2.

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that SEQUIVITY® IAV-S NA (Swine Influenza Vaccine, N1 and N2, RNA Particle) vaccine is commercially available as part of its swine product portfolio. The company received license approval for the vaccine from the U.S. Department of Agriculture (USDA) in 2022.

The SEQUIVITY IAV-S NA vaccine is the first commercial vaccine that uses only the
influenza neuraminidase (NA) surface antigen to vaccinate pigs against influenza strains H1N1, H1N2 and H3N2. The NA RNA particles in the vaccine are produced using the innovative SEQUIVITY platform technology from Merck Animal Health that previously has been used to target existing and emerging swine pathogens.

“Merck Animal Health is excited to bring this important innovation to our customers as it
demonstrates our mission to bring forward solutions to solve swine disease challenges and
improve animal health,” said Channing Sebo-Decker, D.V.M., swine technical services
veterinarian, Merck Animal Health. “The SEQUIVITY IAV-S NA vaccine represents a novel
technological advancement and creates a new tool for influenza control programs.”

The frozen vaccine is mixed with Microsol Diluvac Forte® adjuvant at point of use. Pigs
can be vaccinated as early as three days of age followed by a booster three weeks later. The duration of the immunity against the H1N1 subtype is at least 12 weeks post-booster dose. The licensing trials demonstrated that the vaccine was safe and significantly reduced IAV-associated lung lesions and nasal shedding against five challenge strains from the H1N1, H1N2 and H3N2 subtypes.

SEQUIVITY IAV-S NA vaccine is available in 50-dose and 250-dose presentations. To
learn more about our portfolio of swine health products and vaccines, visit